Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00849186 · ClinicalTrials.gov registry record · NA
Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer
A NA study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT00849186 is a NA study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 20 participants.
The verdict
NCT00849186, a NA study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical trial is studying the side effects of giving sunitinib before surgery and to see how well it works in treating patients with localized or metastatic kidney cancer.
Interventions
- PROCEDURE therapeutic conventional surgery
- DRUG sunitinib malate
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-08 |
| Est. Completion | 2010-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00849186
The ClinicalTrials.gov registry entry for NCT00849186 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which therapeutic conventional surgery is the first listed.
NCT00849186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00849186 about?
NCT00849186 is a clinical study titled "Sunitinib and Surgery in Treating Patients With Localized or Metastatic Kidney Cancer". RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sunitinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This clinical ...
What is the current status of trial NCT00849186?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2007-08. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00849186?
The interventions under investigation include: therapeutic conventional surgery (PROCEDURE), sunitinib malate (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00849186?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.